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Background. Geleophysic dysplasia (OMIM 231050, GD) is an autosomal recessive 
disorder characterized by short stature, small hands and feet, stiff joints and thick skin. 
Patients often present with a progressive cardiac valvular disease which can lead to an early 
death.  In a previous study including six GD families, we have mapped the disease gene on 
chromosome 9q34.2 and identified mutations in the A Disintegrin And Metalloproteinase 
with Thrombospondin repeats-like 2 gene (ADAMTSL2).  
 Methods. Following this study, we have collected the samples of 30 additional GD 
families, including 33 patients and identified ADAMTSL2 mutations in 14/33 patients, 
comprising 13 novel mutations. The absence of mutation in 19 patients prompted us to 
compare the two groups of GD patients, namely group 1, patients with ADAMTSL2 mutations 
(n=20, also including the 6 patients from our previous study) and group 2, patients without 
ADAMTSL2 mutations (n=19).   
 Results. We found that the main discriminating features were facial dysmorphism and 
tip-toe walking, almost constantly observed in group 1. No differences were found concerning 
heart involvement, skin thickness, recurrent respiratory and ear infections, bronchopulmonary 
insufficiency, laryngo-tracheal stenosis, deafness and radiographic features.  
 Conclusions. We conclude that GD is a genetically heterogeneous condition. Ongoing 

















Geleophysic dysplasia (OMIM 231050, GD) is a rare autosomal recessive disorder 
characterized by short stature, small hands and feet, stiff joints, thick skin and pseudo-
muscular hypertrophy [1]. Facial features include round full “happy” face (from the Greek 
geleos : “happy” and physis : “nature”), small nose with anteverted nostrils, long flat 
philtrum, long thin upper lip, broad nasal bridge and narrow palpebral fissures. The 
radiological manifestations include brachymetacarpy/tarsy, delayed bone age, cone-shaped 
epiphyses, shortened long tubular bones and vertebral abnormalities (ovoid vertebral bodies, 
platyspondyly) (Figure 1). 
 Patients often present with a progressive cardiac valvular disease, which may result in 
secondary hypertrophy and cardiac failure leading to death in the first years of life [2]. 
Progressive hepatomegaly, recurrent respiratory infections and tracheal stenosis leading to 
severe respiratory problems are also commonly observed. 
GD belongs to the group of acromelic dysplasias (group 14 of the International Classification 
of Genetic Skeletal Disorders [3]) which also includes acromicric dysplasia (AD) and Weill-
Marchesani syndrome (WMS).  
AD is distinct from GD by the absence of cardiac valvular disease, the presence of distinct X-
ray abnormalities (internal notch of the femoral head, internal notch of the second metacarpal 
and external notch of the fifth metacarpal) and autosomal dominant mode of inheritance. The 
molecular bases remain unknown [5]. 
WMS is characterised by ectopia lentis and microspherophakia and is either due to FBN1 
mutations, responsible for the dominant form [6] or ADAMTS10 mutations, responsible for 
the autosomal recessive form [7]. 
Studying a series of six GD families, we have mapped the disease gene on chromosome 
9q34.2 and identified four distinct missense mutations and a nonsense mutation in the A 
Disintegrin And Metalloproteinase with Thrombospondin repeats-like 2 gene (ADAMTSL2). 
We also identified Latent TGFβ Binding Protein 1 (LTBP1) as a partner of ADAMTSL2 and 
found an enhanced TGFβ signalling in GD fibroblasts, suggesting a role of ADAMTSL2 in 
the regulation of the bioavailability of TGFβ [8]. 
We present here ADAMTSL2 molecular screening in a series of 33 additional GD cases. The 
absence of mutation in a significant number of patients prompted us to compare the clinical 





Diagnosis of GD was assessed by a clinical geneticist. All patients included in the study 
fulfilled the diagnosis criteria for GD: 1) short stature (<-2 SD) 2) short hands and feet 3) stiff 
joints 4) dysmorphic features. Cardiac valve disease and thick skin were not considered as 
mandatory criteria based on their absence in 3/6 cases of our initial series [8]. A systematic 
survey of the skeleton was requested: internal notch of the femoral head or of the second 
metacarpal and external notch of the fifth metacarpal were never mentioned, supporting the 
exclusion of acromicric dysplasia cases. 
11 patients were included in the study through the French reference center for constitutional 
bone disorders in Necker Hospital and 22 patients were diagnosed as GD by clinical 
geneticists from various countries (Belgium, UK, Germany, Netherland, Lebanon, Portugal, 
and Turkey). A total of 33 patients were included (21 males and 12 females), ranging in age 
from 2 months to 26 years and originating from Algeria, Canada, China, England, Italy, 
Japan, Lebanon, Morocco, Pakistan, Portugal, Russia and Turkey. 5 patients were offspring of 
consanguineous relationships (patient 5, 17, 21, 22 and 24), there was one sib pair (patient 32 
and 33) and three cousins (patient 17, 21 and 24). Appropriate written informed consents 
regarding human study were obtained from all subjects.  
 
Mutation analysis 
ADAMTSL2 exon and flanking intron sequences were amplified from patient DNA by PCR 
using 21 couples of primers designed with the Primer 3 software. The amplicons were 
purified and sequenced using the BigDye Terminator Cycle Sequencing Kit v3.1 (Applied 
Biosystems, Foster City, California) on an automatic sequencer (ABI 3100).  
 
Statistical analyses 
A nonparametric Mann-Whitney test was used to compare means and a Chi-square test was 








ADAMTSL2 sequence analysis performed in the 33 patients allowed us to identify 14 distinct 
mutations in 14 patients comprising 13 novel mutations (Table 1).  
Mutations were present at the homozygous state in 5 cases while patients were compound 
heterozygous in 6 other cases. In three cases (4, 7 and 15) only a single heterozygous 
mutation, inherited from the mother, was detected. 
The mutations were located throughout the gene (Figure 2). Among them, one mutation was a 
nonsense mutation (p.[R425X]), one was a 30 bp deletion affecting the N glycan-rich module 
(c.[1148_1177del]) and eleven were missense mutations (p.[W50C], p.[R72Q], p.[E114K], 
p.[R159W], p.[A165T], p.[C171R], p.[R221C], p.[A239T], p.[R593C], p.[S635L] and 
p.[P906L]). We also identified the p.[C407C] mutation which was predicted to alter splicing 
but mRNA was not available for this patient. Except for p.[E114K], none of these mutations 
had been previously described. All mutations cosegregated with the disease and were not 
identified in 200 control chromosomes. The missense mutations consistently involved 
residues conserved across species and across the ADAMTSL family members. The prediction 
program PolyPhen was queried for the reported missense mutations and all of them were 
predicted to have a damaging role.  
The absence of mutation in 19/33 patients (58%) prompted us to compare the clinical and 
radiological features of the two groups of GD patients (Table 2), namely group 1, patients 
with ADAMTSL2 mutations (n=20, also including the 6 patients from our initial study [8]) and 
group 2, patients without ADAMTSL2 mutation (n=19). Importantly, blinded comparison was 
made by clinical geneticists unaware of the molecular diagnosis. 
No consanguinity was found in group 2 whereas half of the families of group 1 were 
consanguineous. Antenatal history showed polyhydramnios, and prenatal growth retardation 
in 91% and 76% of group 1 patients, versus 18% and 31% of group 2 respectively. Birth term 
was two weeks earlier in group 1 (because of a higher proportion of induced deliveries due to 
prenatal growth retardation) and birth head circumference was normal for the term in both 
groups. The mean height was lower than -4 SD in both groups but short stature was more 
severe in group 2 (-5.8 versus -4.1 SD). Tip-toe walking (restriction of dorsiflexion of the feet 
as a consequence of the extreme joint limitations and contractures) was almost constantly 
observed in group 1 whereas it was rarely reported in group 2 (88% versus 18%). Concerning 
facial dysmorphism, thin upper lip, long flat philtrum and narrow palpebral fissures were 
much more frequent in group 1 than in group 2 (Figure 3). No significant difference was 
found concerning heart involvement and skin thickness (which were observed in 
approximately 70 % of both groups), recurrent respiratory and ear infections, 
bronchopulmonary insufficiency, laryngo-tracheal stenosis, high pitched voice, hepatomegaly, 
ophthalmologic symptoms, deafness and radiographic features (delayed bone age, cone-
shaped epiphyses, shortened long tubular bones, abnormal femoral heads, platyspondyly and 
ovoid vertebral bodies). One patient from group 1 had a severe systemic hypertension. 
However the long-term follow up of patients from both groups did not reveal any difference 
in the course of the disease. Two mutated patients and five non mutated patients died of 
cardiorespiratory failure (mean age 3.6 years). 
 
DISCUSSION 
We report here the identification of 14 ADAMTSL2 mutations in 14/33 GD patients (42%), 
comprising 13 novel mutations located throughout the gene, with a majority of missense 
mutations involving highly conserved residues. 
The absence of identified mutations in 58% of GD patients may have different explanations. 
First, only direct sequencing of ADAMTSL2 was performed. One cannot exclude partial 
intragenic deletions or mutations in the introns or promoter region. This is probably the case 
for at least three patients (4, 7 and 15) where only a single heterozygous mutation was 
detected. However, the limit of our screening probably does not account for such a high 
proportion (58%) of non mutated patients. 
The absence of identified mutation could be also due to overlapping diagnosis. Indeed GD is 
closely related to AD which is the main differential diagnosis and the distinction can be 
difficult especially in the absence of cardiac valvular disease [9]. Importantly, recurrent sibs 
or consanguineous parents were never observed in the non mutated patients group. However, 
all patients fulfilled the diagnosis criteria for GD and at least 9 non mutated patients presented 
with characteristic valvular cardiac disease.  
Finally, we did not find any significant difference in the main clinical and radiological 
features characteristic of GD, namely cardio-respiratory involvement, skin thickness, 
laryngeal stenosis, hepatomegaly, natural history of the disorder and severe outcome. By 
contrast, we found minor discriminating features including facial dysmorphism (thin upper 
lip, long flat philtrum and narrow palpebral fissures) and tip-toe walking, only consistently 
observed in ADAMTSL2 mutated group. 
Our study supports that GD is a genetically heterogeneous condition with ADAMTSL2 
mutations being identified in 42% of GD patients. Ongoing studies will hopefully lead to the 
identification of another GD gene presumably also involved in TGFβ bioavailability. 
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Legends to figures 
 
Figure 1: Skeletal manifestations of geleophysic dysplasia. (a) Hand X-rays of patient 3 at age 
3 years (top) and age 10 years (bottom). Note the very small hand with short and plump 
tubular bones and cone-shaped epiphyses (arrow). Note also the carpal ossification delay. (b) 
Hip and lower limbs X-ray of patient 4 at age 8 months. Note the small capital femoral 
epiphyses and the shortened long tubular bones. (c) AP view of the spine of patient 12 at age 
1 year. Note the ovoid vertebral bodies. 
 
Figure 2: ADAMTSL2 mutations 
In Italic: ADAMTSL2 mutations previously identified (Le Goff et al., 2008) 
In Non-Italic: novel mutations  
 
Figure 3: Clinical manifestations of geleophysic dysplasia in patient 28 (mutated in 
ADAMTSL2) and patient 31 (not mutated in ADAMTSL2). (a,e) Note the short stature, small 
hands and feet, stiff joints and pseudo-muscular hypertrophy (patient 28 at age 9 years and 
patient 31 at age 4 years). (b,f,g) Note the very small hands and feet. (c) Note the tip-toe 
walking. (d,h) Note the common facial features, including round full face, small nose with 
anteverted nostrils and long philtrum (patient 28 at age 6 years and patient 31 at age 4 years). 
Note also the thin upper lip, broad nasal bridge and narrow palpebral fissures present only in 
patient 28 (mutated in ADAMTSL2). Informed consent was obtained to publish the 





















 Patient Ethnic 
Origin 
Identified mutation Position ADAMTSL2 
affected domain 
Protein 
2 France c.[150G>T]+ 
[1273C>T] 
Ex 2 / Ex 9 TSR 1/ N glycan 
rich domain 
p.[W50C]+[R425X] 
4 France c.[1148_1177del] Ex 9/? N glycan rich 
domain 
p.Asn383_Asp392del 
5 Turkey c.[493G>A] Ex 5  CRD  p.[A165T] 
7 France c.[340G>A]   Ex 4/? CRD  p.[E114K] (*) 
12 France c.[475C>T]+[511T>C] Ex 5 CRD  p.[R159W]+[C171R] 
15 Japan c.[2717C>T] Ex17/? PLAC p.[P906L] 
17 Pakistan c.[661C>T] Ex 6  Spacer  p.[R221C] 
21 Pakistan c.[661C>T] Ex 6  Spacer  p.[R221C] 
22 Italy c.[715.G>A] Ex 7 Spacer  p.[A239T] 
24 Pakistan c.[661C>T] Ex 6 Spacer p.[R221C] 
28 England c.[215G>A]+ [340G>A] Ex 2/ Ex 4  TSR1/ CRD p.[R72Q]+p.[E114K] 
30 France c.[1219C>T]+ 
[1904C>T] 
Ex 9/ Ex 
13 
N glycan rich 
domain/TSR 3 
p.[C407C]+p.[S635L] 
32 England c.[150G>T]+ 
[1777C>T] 





33 England c.[150G>T]+ 
[1777C>T] 






Table 1: ADAMTSL2 mutations identified in our series. 



























  Group 1 : mutated  
(n = 20) 
Group 2 : non mutated 
(n = 19) 
P 
Consanguinity 10/20 0/16  0.003 
Polyhydramnios 10/11  2/11  0.003 
Prenatal growth retardation 13/17  4/13  0.03 
Birth term (weeks of 
amenorrhea) 
37.5 +/-2.1 (3 NA) 39.7 +/-1.1 (5 NA) 0.004 
Birth length (cm) 44.6 +/-3.0 (5 NA) 48.9 +/-1.6 (8 NA) 0.0004 
Birth head circumference (cm) 33.5 +/-1.7 (4 NA) 35.7 +/-1.1 (11 NA) 0.002 
Cardiac valvular anomaly 14/18  9/13  0.89 
Pulmonary arterial hypertension 4/11  5/9  0.42 
Cardiac surgery 3/14  4/9  0.47 
Recurrent respiratory and ear 
infections 
8/12  8/15  0.75 
Bronchopulmonary insufficiency 8/16  7/15  0.62 
Laryngotracheal stenosis 6/13  7/14  0.99 
Decease (of cardiorespiratory 
failure) 
2/20 5/19 0.36 
Deafness 8/13  6/13  0.69 
Ophthalmologic symptoms 8/13  3/12  0.15 
Mild mental retardation 6/15  5/17  0.80 
Height (SD) - 4.1 +/-1.0 (6 NA) - 5.8 +/-2.4 (3 NA) 0.016 
Head circumference (SD) -0.9 +/-1.7 (11 NA) 0.0 +/-1.2 (5 NA) 0.15 
Tip-toe walking 14/16  2/11  0.001 
Thickened skin  10/15  9/13  0.99 
Pseudo-muscular hypertrophy 11/14  7/14  0.24 
Hepatomegaly  5/17  9/16  0.22 
High pitch voice 6/11  1/7  0.22 
Round full face 14/15  9/16  0.05 
Small nose 11/16  13/15  0.41 
Broad nasal bridge 14/15  11/15  0.33 
Long flat philtrum 18/19  10/17  0.027 
Thin upper lip 18/18  6/15   0.005 
Narrow palpebral fissures 13/15  7/17  0.03 
Delayed bone age 12/13  12/13  0.99 
Cone-shaped epiphyses 5/8  8/12  0.99 
Shortened long tubular bones 15/15  9/11  0.33 
Small and/or irregular femoral 
epiphyses  
8/10  6/12  0.31 
Platyspondyly 5/8  2/9  0.22 
Ovoid vertebral bodies 6/10  7/11  0.99 
NA = not available 
 
Table 2: Comparison of GD patients with ADAMTSL2 mutations (group 1) and without 
ADAMTSL2 mutation (group 2). 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 



